IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

"The Far-Reaching Consequence Of Chronic Kidney Disease: A Review Of Complication And Management Strategies."

SAFNA FAISAL*[1], FARHANA N[1], SURYA S NAIR[1],

DR. NITHIN MANOHAR R[2], DR. PADMESH P R[3], DR. PRASOBH G R[4]

[1]5th Year Doctor of Pharmacy Student, Sree Krishna College of Pharmacy and Research Centre, Parassala, Trivandrum, Kerala.

[2] Professor and HOD, Department of Pharmacy Practice, Sree Krishna College of Pharmacy and Research Centre, Parassala, Trivandrum, Kerala.

[3]Assistant Professor, Department of Pharmacy Practice, Sree Krishna College of Pharmacy and Research Centre, Parassala, Trivandrum, Kerala.

[4]Principal, Sree Krishna College of Pharmacy and Research Centre, Parassala, Trivandrum, Kerala.

ABSTRACT

Chronic kidney disease affects 10–13% of people, is gradual, irreversible, and linked to an increased risk of cardiovascular disease. Most of the time, patients with this condition do not exhibit any symptoms; only in more advanced stages do they show the normal problems of renal failure. Treatment options include replacement therapy (haemodialysis, peritoneal dialysis, and kidney transplantation) or conservative care (patients without a dialysis indication, typically those with a glomerular filtration rate greater than 15 ml/minute). Slowing the course of renal dysfunction, treating comorbidities (such as anaemia, bone disorders, and cardiovascular illnesses), being vaccinated against hepatitis B, and getting ready for kidney replacement therapy are the goals of conservative treatment for chronic kidney disease.

KEY WORDS

CKD, eGFR, ABPM, RAAS, ESRD, ACR, CVD, LMIC.

INTRODUCTION

Regardless of the cause, kidney damage or an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m² that lasts for three months or longer are indicators of chronic kidney disease (CKD).[1] Chronic kidney disease (CKD) is characterised by a progressive decrease of kidney function that eventually necessitates renal replacement therapy, such as dialysis or transplantation. Increased urinary albumin excretion rates, anomalies in urine sediment, or pathologic abnormalities indicated by imaging tests or renal biopsies are all considered forms of kidney impairment.

The consequences of chronic kidney disease (CKD) are wide-ranging; it arises from multiple disease processes and impacts blood pressure, anaemia, bone metabolism, cardiovascular health, cognitive function, and numerous other health markers. Different techniques for testing eGFR have been reported, and the first step in treating CKD is early detection. The course of CKD is influenced by risk factors that may be changed as well as those that cannot. In order to halt the progression of CKD, management entails addressing reversible causes, planning for renal replacement therapy, and modifying pharmaceutical dosages in accordance with the patient's eGFR.[2] This exercise examines the causes, symptoms, and treatment of chronic kidney disease (CKD), highlighting the critical function of an interdisciplinary healthcare team in delivering all-encompassing care. Both controllable and non-modifiable risk factors are the focus of an interprofessional approach to manage and reduce the advancement of the disease

ETIOLOGY

Type 2 diabetes (between 30% and 50%)
• 3.9% have type 1 diabetes.
• 27.2% hypertension
8.2% have primary glomerulonephritis.
• 3.6% of patients have chronic tubulointerstitial nephritis.
• Cystic or hereditary illnesses (3.1%)
• Vasculitis or secondary glomerulonephritis (2.1%).
• Neoplasms or plasma cell dyscrasias (2.1%).
• In the US, sickle cell nephropathy affects less than 1% of people with end-stage renal disease.

EPIDEMIOLOGY

Since the early to intermediate stages of CKD are asymptomatic, it is difficult to estimate the true incidence and prevalence of the disease. It is believed that between 10% and 14% of the general population has chronic kidney disease. In particular, the prevalences of albuminuria and an eGFR below 60 mL/min/1.73 m² are approximately 7% and 4%, respectively.[3] In 2012, CKD caused 2,546,700 (1%–3%) and 2,968,600 (1%) disability-adjusted life years to be lost globally.[4] An estimated 26 million Americans suffered from CKD in 2016.[5] According to the Kidney Disease Outcomes Quality Initiative (KDOQI), patients should undergo testing three times over the course of three months in order to diagnose chronicity and chronic kidney disease (CKD), with at least two of the three tests coming back positive.[6]

Risk Factors for Progression of Chronic Kidney Disease

Non-modifiable CKD risk factors: The advancement of CKD is negatively impacted by older age, male gender, and non-White ethnicity, including Asians (South Asians and Pacific Asians), Black Americans, Afro-Caribbean people, Hispanics, and others. Numerous renal disorders have been found to have genetic variables that influence the course of CKD. Single nucleotide variations in the genes TCF7L2 and MTHFS were linked to diabetic nephropathy and the advancement of chronic kidney disease (CKD), according to a

population-based cohort analysis. The same study also showed that CKD progression is influenced by polymorphisms in genes related to renal scarring and the renin-angiotensin-aldosterone system (RAAS).[7]

Modifiable CKD risk factors: These consist of metabolic variables, proteinuria, and systemic hypertension.[8] After diabetes, systemic hypertension is the second most common cause of ESRD in the US and a substantial contributor to the disease globally. It is thought that the development of glomerulosclerosis is aided by the transfer of systemic hypertension into glomerular capillary beds and the glomerular hypertension that results.[9] Compared to normal measurements, there is a stronger correlation between the progression of CKD and blood pressure readings taken at night and throughout the day (such as ambulatory blood pressure monitoring, or ABPM). In particular, systolic blood pressure is linked to problems in CKD and is a critical predictor of CKD progression.[10]

The RAAS system has been connected in numerous studies to the onset of renal fibrosis, proteinuria, and hypertension in CKD. Because RAAS-targeting therapies have been successful in delaying the course of CKD, RAAS blockers are now commonly used to treat proteinuric and diabetic renal disorders. Smoking and obesity have been linked to the onset and advancement of chronic kidney disease. Furthermore, the onset and advancement of CKD have been linked to metabolic variables such insulin resistance, dyslipidaemia, and hyperuricemia.[11][12]

Pathophysiology

Chronic and prolonged insults from progressive nephropathies cause continuous kidney fibrosis and the breakdown of normal kidney architecture, in contrast to acute kidney injury (AKI), which frequently leads to full functional recovery. The kidney's glomeruli, tubules and interstitium, and arteries are all impacted by this process. It shows up histologically as vascular sclerosis, tubulointerstitial fibrosis, and glomerulosclerosis.[13]

The following are intricate, overlapping, multi-stage processes that result in scarring and fibrosis:

- Extrinsic inflammatory cells infiltrate injured kidneys.
- Intrinsic renal cell activation, proliferation, and loss (due to mesangiolysis, necrosis, apoptosis, and podocytopenia).
- The activation and growth of cells that produce extracellular matrix, such as fibroblasts and myofibroblasts.
- Extracellular matrix is deposited in place of the typical architecture.[14]



Mechanisms of Accelerated Progression of Chronic Kidney Disease

Changes in prostanoid metabolism, intrarenal precipitation of calcium phosphate, glomerular hypertrophy, and systemic and intraglomerular hypertension[15] A histological condition known as glomerulosclerosis is the result of all these processes.[16] Black race, hypertension, proteinuria, and hyperglycemia are clinical risk factors for the faster advancement of chronic kidney disease.[17] The faster course of chronic kidney disease (CKD) has also been associated with environmental exposures, including obesity, smoking, lead, metabolic syndrome, and certain analgesics.[18]



Staging

The 6 categories of CKD staging include:

- G1: GFR 90 mL/min/1.73 m2 and higher with renal disease-related urine abnormalities, such as proteinuria or haematuria
- G2: 60–89 mL/min/1.73 m2 GFR
- GFR 45 to 59 mL/min/1.73 m2 for G3a
- GFR 30 to 44 mL/min/1.73 m2 for G3b
- G4: 15–29 mL/min/1.73 m2 GFR
- G5: ESRD or GFR < 15 mL/min/1.73 m2.

ACR is one of the three stages of albuminuria:

- A1: ACR <3.4 mg/mmol (less than 30 mg/g)
- ACR 30–299 mg/g (3.4–34 mg/mmol) in A2
- ACR > 300 mg/g (>34 mg/mmol) is A3.

Stage of CKD	eGFR result	What it means
Stage 1	90 or higher	- Mild kidney damage - Kidneys work as well as normal
Stage 2	60-89	- Mild kidney damage - Kidneys still work well
Stage 3a	45-59	- Mild to moderate kidney damage - Kidneys don't work as well as they should
Stage 3b	30-44	- Moderate to severe damage - Kidneys don't work as well as they should
Stage 4	15-29	- Severe kidney damage - Kidneys are close to not working at all
Stage 5	less than 15	- Most severe kidney damage - Kidneys are very close to not working or have stopped working (failed)

COMPLICATION OF CKD

1. ***Hypertension:*** One of the most harmful side effects of chronic kidney disease (CKD) is hypertension, which is also believed to hasten the progressive deterioration of kidney function, cardiovascular disease (CVD), and associated mortality. Improvements could directly benefit patients, as both the detection and management of high blood pressure are often inadequate.[19] The Systolic Blood Pressure Intervention Trial excluded high-risk participants with diabetes, proteinuria, or CKD, but it did offer valuable insights into the effects of a stricter lowering of systolic blood pressure to a target of <120 mm Hg that may be pertinent to CKD patients.[20]. Changes in lifestyle, such losing weight and limiting salt in the diet, may also help manage blood pressure. These treatments may be less expensive than pharmaceutical treatments and may influence outcomes like heart failure and stroke in both low- and middle-income (LMIC) and developed health care systems. One realistic objective would be to enhance the management of high blood pressure issues in patients with chronic kidney disease (CKD), with the goal of achieving target ranges in a percentage of patients, given the abundance and affordability of anti-hypertensive medications in LMICs. Such an objective may be accomplished on a worldwide scale, and its effects are readily quantifiable.
2. ***Cardiovascular complications:*** In patients with chronic kidney disease (CKD), cardiovascular disease (CVD) is the primary cause of death. As kidney function declines, the prevalence and burden of this consequence rise (Figures 1 and 2).8, For instance, compared to a reference population free of renal disease, patients with CKD stage G5 A3 (eGFR < 15 ml/min per 1.73 m2 and urine albumin-creatinine ratio > 300 mg/g) have an 8.1-fold higher risk of dying from CVD.4. Although CKD raises the risk of traditional atherosclerotic cardiovascular events, non-atherosclerotic pathologies such valve disease, arterial calcification, and left ventricular hypertrophy with diastolic and systolic dysfunction account for the majority of the elevated risk. Heart failure, sudden death, and atrial and ventricular dysrhythmias are some of the symptoms of these disorders. There are other risk factors to take into account in CKD patients, the majority of which are regarded as CKD complications, even though it is widely acknowledged that treating traditional cardiovascular risk factors like blood pressure17 and cholesterol16 is effective in the CKD population, especially in patients with CKD stages 1 to 3. Cardiomyopathy and vasculopathy, for instance, may be exacerbated by endocrine and mineral abnormalities that are indicative of CKD-mineral bone disease, such as phosphate retention, increased fibroblast growth factor 23, and abnormalities in Klotho metabolism. 18A worldwide

decrease in the burden of CVD attributable to CKD may eventually result from advances in our knowledge of the factors that contribute to CVD associated with CKD, the discovery of new therapeutic targets, blood pressure control initiatives, and the increased prescription of lipid-lowering medications.[21]



3. ***Anemia:*** Iron and erythropoiesis-stimulating agents (ESAs) have been used to address anaemia problems in patients with chronic kidney disease (CKD) in various regions of the world. The ideal dosages of parenteral iron and ESAs have not yet been determined, yet. Although ESAs can alleviate symptoms, it is yet unknown how these drugs affect survival and they may raise the risk of cancer and cardiovascular disease. The entire range of ESA's adverse effects is unknown, and little is known about how elevated hepcidin contributes to CKD.[22] Patients may be more vulnerable to the negative effects of these expensive medications due to regional variations in resistance to ESA therapy. In many LMICs, where ESAs are scarce and prohibitively expensive, the present approach to treating anaemia in patients with chronic kidney disease differs from that of affluent nations, where these drugs are commonly accessible. Although more research is needed to fully understand the dangers and advantages of intravenous iron and ESAs, efforts to increase access to these treatments (as well as blood transfusions) in LMICs may lessen the burden of anaemia symptoms in CKD.
4. ***CKD-related mineral bone disorder:*** Kidney Disease: Improving Global Outcomes23,24,25 recommendations described the syndrome of CKD-mineral and bone problem, which includes soft tissue calcification, the range of renal osteodystrophy, and conventional mineral biochemical abnormalities. These anomalies may be causally related to left ventricular hypertrophy. Despite a large amount of preclinical evidence, very few advancements have been applied to clinical applications, and this complex set of illnesses is poorly understood[23]. Although it is possible to monitor and treat secondary hyperparathyroidism, high blood phosphate levels, and vitamin D deficiency, the actual advantages of correcting these abnormalities have not been established. Because inexpensive calcium-based phosphate binders have the potential to worsen tissue calcium deposition, their application is debatable. Increasing the availability of phosphate binders, nutritional vitamin D, and 1,25-dihydroxyvitamin D analogues would be a practical strategy based on our present understanding of the condition to reduce the known symptoms of tertiary hyperparathyroidism.

5. ***Salt and water retention:*** Defence against both excess and depletion of sodium is lost in CKD stages 4 to 5, and perhaps in CKD stage 3. Although the precise incidence has not been established, sodium overload with fluid retention is by far the most prevalent condition in clinical practice. Up until end-stage renal failure, the sodium balance seems to be mostly maintained, despite the possibility of an expansion of the extracellular fluid volume.[24]Excess fluid and sodium cause hypertension and therefore CVD (particularly concentric left ventricular hypertrophy, which can lead to diastolic dysfunction) in addition to oedema, which can impair quality of life. Adherence to basic fluid balance (intake vs. output) principles, dietary salt restriction, and the use of natriuretic agents—which may be less effective in the more advanced stages of CKD—are the cornerstones of treatment. Since they are readily accessible and reasonably priced, thiazides and loop diuretics may be used more frequently to reduce CKD patients' symptomatic oedema and potentially enhance cardiovascular outcomes.
6. . ***Metabolic acidosis and electrolyte disorders:*** When acid synthesis and ingestion surpass renal acid excretion, metabolic acidosis, a prevalent condition in chronic kidney disease, results. Because of buffering and renal adaptation, it may initially show up as "acid excess with normal bicarbonate," which is a condition of positive acid balance without low plasma bicarbonate.[25] Alkali therapy works well, however it is constrained by required potassium and/or sodium doses. Chronic metabolic acidosis may hasten the course of chronic kidney disease (CKD) and is linked to bone disease, skeletal muscle catabolism, and insensitivity to endocrine hormones.[26] Finding potentially hazardous acid loading before a drop in serum bicarbonate happens is the difficulty of early detection. Because the therapies are cheap, metabolic acidosis could be treated globally. However, the benefits of this intervention have not been established, and the sodium or potassium loading that comes with current alkali therapy may be detrimental, especially in more advanced stages of CKD. Alternative methods of delivering alkali are required. Alkalis that don't contain sodium or potassium are being developed, but availability and cost are probably going to be issues, especially in LMICs. In an attempt to lessen suffering, sodium bicarbonate is currently being used more widely to treat symptomatic metabolic acidosis in advanced chronic kidney disease.
7. ***Uremic symptoms:*** Anorexia, exhaustion, cachexia, pruritus, nausea, restless legs syndrome, sleep difficulties, and sexual dysfunction are some of the symptoms that make up the uremia syndrome.[27] Pruritus is widespread and can negatively impact one's quality of life. Although the exact causes are unknown, the buildup of certain uremic toxins in the skin is probably one of them. It's critical to distinguish uremic irritation from itching brought on by other illnesses since treatment options may differ. LMIC has access to antihistamines and topical treatment. The availability of other medications, such gabapentin and opioid receptor modulators, is probably going to be more restricted. For at least some people, pruritus may be effectively relieved by treating hyperparathyroidism and hyperphosphatemia. A similar and sometimes incapacitating clinical diagnosis is restless leg syndrome.[28] While this issue is known to occur in people with normal renal function, CKD and dialysis patients are far more likely to have it. Sleep disturbance, sadness, poor quality of life, increased cardiovascular morbidity, and increased mortality are all linked to pruritus and restless legs syndrome. Although the pathophysiology is uncertain, it can be indicative of a generalised state of ill health. Exercise and a number of medications, such as gabapentin, dopaminergic modulators, serotonin antidepressants, and lithium, can help reduce the symptoms of restless leg syndrome. Despite the paucity of research regarding these therapies' effectiveness, they are available in numerous LMICs.



Infectious Complications in Chronic Kidney Disease

One major cause of morbidity and mortality in people with chronic kidney disease (CKD) is infectious complications.[29] Despite the fact that some of these occurrences may be avoided, little attention has been paid to the entire breadth of significant infectious consequences. We compared the infection hospitalisation rates in the populations with chronic kidney disease (CKD) and end-stage renal disease (ESRD) to those without these conditions. To identify areas for possible improvement, we also examined the rates of influenza, pneumonia, and pneumococcal pneumonia preventative vaccinations. Based on hospitalisation rates for pneumonia, sepsis/bacteremia, and urinary tract infections in Medicare CKD, ESRD, and non-CKD populations, we evaluated the medical literature and presented our findings. Claims that were submitted for services with certain vaccination codes were used to calculate vaccination rates. Patient outcomes following the onset of infections were three to four times worse than in the non-CKD group, regardless of whether the development of CKD was due to primary renal disease, hypertension, diabetes mellitus, or another chronic condition. Compared to the goal of 90%, influenza vaccination rates were only 52%. The 13.5% immunisation rate for pneumococcal pneumonia was significantly below the recommended level. Significant severe infection complications are linked to chronic kidney disease (CKD) and occur three to four times more frequently than in the general population. Reducing the use of dialysis catheters and raising influenza and pneumococcal pneumonia vaccination rates are two ways that providers can enhance prevention.

Infections in CKD Patients

Compared to the ESRD population, the scale of the morbidity has not garnered as much attention, despite research addressing host defence anomalies in the CKD population.[30]

Pneumonia rates are three times higher in the CKD population and five times higher in the dialysis group as compared to the non-CKD population. Especially noteworthy is the length

In order to concentrate future efforts on reducing the morbidity and mortality brought on by CKD complications globally[31], the work group established the following particular aims.

Treatment / Management

General Management

• The patient's eGFR readings should be taken into consideration while adjusting medication dosages.
• Surgical referrals for the implantation of haemodialysis or peritoneal dialysis access, as well as for transplantation when necessary, should be made as part of the preparation for renal replacement therapy.

Treatment of Reversible Causes of Renal Failure

It is important to identify and treat potentially reversible causes of AKI, such as infections, medications, hypotension, and hypovolemia. Before performing intravenous contrast investigations, patients with chronic kidney disease (CKD) should be thoroughly examined, and other options should be explored first. Nephrotoxic substances should also be avoided, such as nonsteroidal anti-inflammatory medications (NSAIDs) and aminoglycoside antibiotics.

Slowing the Progression of Chronic Kidney Disease

It is important to treat the factors that contribute to the advancement of chronic kidney disease (CKD), such as metabolic acidosis, proteinuria, hypertension, and hyperlipidaemia. Proteinuria should be decreased to less than 1 g/d if at all possible, and hypertension should be controlled in accordance with established blood pressure targets.[33]
Numerous studies have demonstrated that quitting smoking slows the progression of chronic kidney disease (CKD) and is linked to an increased risk of nephrosclerosis.[34] It has also been demonstrated that protein restriction slows the course of CKD. Dietician involvement is essential because individuals with advanced chronic kidney disease are susceptible to malnutrition.

It has been shown that treating chronic metabolic acidosis with bicarbonate supplements can slow the course of CKD.[35] Furthermore, it has been shown that strict glucose management in diabetics can postpone the development of albuminuria and stop it from developing into overt proteinuria.[36]

Patients should be given the following choices for renal replacement treatment when stage 4 CKD progression has been identified.
• Home or in-center haemodialysis.
• Intermittent or continuous peritoneal dialysis.
• Living or deceased donor kidney transplantation: Because of its better long-term results, this is the preferred treatment for end-stage renal disease.
• Patients should be informed about conservative and palliative care management if they refuse renal replacement therapy.
•Once steady vascular access has been established in the nondominant arm, haemodialysis is carried out. In order to protect the veins in this arm, intravenous cannulas should be avoided. An AV fistula is the ideal vascular access. Tunnelled haemodialysis catheters and AV grafts are additional haemodialysis access methods. Because of its high patency rates and low infection rates, AV fistulas are recommended.

• After a peritoneal catheter is inserted, peritoneal dialysis is carried out.[37]

Indications for Renal Replacement Therapy

• An urgent indication of pleuritis or pericarditis.
• Asterixis, myoclonus, seizures, and confusion are symptoms of progressive uremic encephalopathy or neuropathy (emergent indication).
• Uremia-related bleeding diathesis that is clinically substantial (emergent indication).
• Antihypertensive drugs don't work well for hypertension.
Fluid excess that is resistant to diuretics.
• Metabolic diseases, including metabolic acidosis, hyperkalaemia, hyponatraemia, hyperphosphatemia, and hypocalcaemia, that do not respond to medical treatment.
• Constant vomiting and nausea.
• Proof of malnourishment.
• Any other uremic symptoms or indicators.

CONCLUSION

A number of problems are associated with progressive chronic kidney disease (CKD), and these consequences are more common and more severe as the disease progresses. Poor quality of life, severe morbidity, and mortality are the results of these problems. We have listed three main objectives (backed by sets of activities) aimed at lessening the negative effects of CKD-related consequences on population health. great knowledge gaps still exist, and the best approaches to particularly close these gaps are still unknown, despite the fact that there has been great progress in characterising CKD-related difficulties across regions and nations.

This is the first effort to create a framework for a coordinated strategy to gain a deeper understanding of these illnesses. This entails developing practice and policy guidelines for optimal care, as well as enhancing our comprehension of the range of pathophysiology and mechanistic pathways, clinical presentations, and phenotypes. We have created an action plan as part of this International Society of Nephrology project to improve our knowledge of the uremic symptoms that have the biggest effects on CKD patients' quality of life, their causes, and the most effective ways to manage them.

References

1. Chapter 1: Definition and classification of CKD. Kidney Int Suppl (2011). 2013 Jan;3(1):19-62.

2. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, Kurella Tamura M, Feldman HI. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014 May;63(5):713-35.

3. Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet. 2017 Mar 25;389(10075):1238-1252.

4. Textor SC. Ischemic nephropathy: where are we now? J Am Soc Nephrol. 2004 Aug;15(8):1974-82.

5. Kitamoto Y, Tomita M, Akamine M, Inoue T, Itoh J, Takamori H, Sato T. Differentiation of hematuria using a uniquely shaped red cell. Nephron. 1993;64(1):32-6.

6. Khanna R. Clinical presentation & management of glomerular diseases: hematuria, nephritic & nephrotic syndrome. Mo Med. 2011 Jan-Feb;108(1):33-6.

7. Aeddula NR, Baradhi KM. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 22, 2023. Reflux Nephropathy.

8. Klahr S. Obstructive nephropathy. Intern Med. 2000 May;39(5):355-61.

9. Rishor-Olney CR, Hinson MR. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 22, 2023. Obstructive Uropathy.

10. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003 Jan;41(1):1-12.

11. Schrauben SJ, Jepson C, Hsu JY, Wilson FP, Zhang X, Lash JP, Robinson BM, Townsend RR, Chen J, Fogelfeld L, Kao P, Landis JR, Rader DJ, Hamm LL, Anderson AH, Feldman HI. Insulin resistance and chronic kidney disease progression, cardiovascular events, and death: findings from the chronic renal insufficiency cohort study. BMC Nephrol. 2019 Feb 20;20(1):60.

12. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266.

13. Muntner P. Longitudinal measurements of renal function. Semin Nephrol. 2009 Nov;29(6):650-7.

14. Kshirsagar AV, Bang H, Bomback AS, Vupputuri S, Shoham DA, Kern LM, Klemmer PJ, Mazumdar M, August PA. A simple algorithm to predict incident kidney disease. Arch Intern Med. 2008 Dec 08;168(22):2466-73.

15. Luttropp K, Lindholm B, Carrero JJ, Glorieux G, Schepers E, Vanholder R, Schalling M, Stenvinkel P, Nordfors L. Genetics/Genomics in chronic kidney disease--towards personalized medicine? Semin Dial. 2009 Jul-Aug;22(4):417-22.

16. Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012 Jan 14;379(9811):165-80.

17. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. J Am Soc Nephrol. 2001 Jun;12(6):1315-1325.

18. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ., ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008 Dec 04;359(23):2417-28.

19.Vidt DG. Telmisartan, ramipril, or both in patients at high risk for vascular events. Curr Hypertens Rep. 2008 Oct;10(5):343-4.

Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet. 1982 Dec 11;2(8311):1309-11.

20.Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study

Am J Kidney Dis, 55 (2010), pp. 441-451 .

21. SPRINT Research Group, J.T. Wright Jr., J.D. Williamson, *et al.* A randomized trial of intensive versus standard blood-pressure control N Engl J Med, 373 (2015), pp. 2103-2116.

22. A.S. Go, G.M. Chertow, D. Fan, *et al.* Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Eng J Med, 351 (2004), pp. 1296-1305.

23. C. Wanner, K. Amann, T. Shoji The heart and vascular system in dialysis Lancet, 388 (2016), pp. 276-284 .

23. C. Baigent, M.J. Landray, C. Reith, *et al.* The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet, 377 (2011), pp. 2181-2192

24.X. Xie, E. Atkins, J. Lv, *et al.* Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.

25. Johnson RJ, Nakagawa T, Jalal D, Sánchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant. 2013 Sep;28(9):2221-8.

26. Anderson S, Rennke HG, Brenner BM. Antihypertensive therapy must control glomerular hypertension to limit glomerular injury. J Hypertens Suppl. 1986 Dec;4(5):S242-4.

27. Yu HT. Progression of chronic renal failure. Arch Intern Med. 2003 Jun 23;163(12):1417-29.

28. Gounden V, Bhatt H, Jialal I. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 27, 2024. Renal Function Tests.

29. Anderson AH, Xie D, Wang X, Baudier RL, Orlandi P, Appel LJ, Dember LM, He J, Kusek JW, Lash JP, Navaneethan SD, Ojo A, Rahman M, Roy J, Scialla JJ, Sondheimer JH, Steigerwalt SP, Wilson FP, Wolf M, Feldman HI., CRIC Study Investigators. Novel Risk Factors for Progression of Diabetic and Nondiabetic CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2021 Jan;77(1):56-73.e1.

30. Methven S, Traynor JP, Hair MD, St J O'Reilly D, Deighan CJ, MacGregor MS. Stratifying risk in chronic kidney disease: an observational study of UK guidelines for measuring total proteinuria and albuminuria. QJM. 2011 Aug;104(8):663-70.

31. Aitekenov S, Gaipov A, Bukasov R. Review: Detection and quantification of proteins in human urine. Talanta. 2021 Feb 01;223(Pt 1):121718.

32. Sumida K, Nadkarni GN, Grams ME, Sang Y, Ballew SH, Coresh J, Matsushita K, Surapaneni A, Brunskill N, Chadban SJ, Chang AR, Cirillo M, Daratha KB, Gansevoort RT, Garg AX, Iacoviello L, Kayama T, Konta T, Kovesdy CP, Lash J, Lee BJ, Major RW, Metzger M, Miura K, Naimark DMJ, Nelson RG, Sawhney S, Stempniewicz N, Tang M, Townsend RR, Traynor JP, Valdivielso JM, Wetzels J, Polkinghorne KR, Heerspink HJL., Chronic Kidney Disease Prognosis Consortium. Conversion of Urine Protein-Creatinine Ratio or Urine Dipstick Protein to Urine Albumin-Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis : An Individual Participant-Based Meta-analysis. Ann Intern Med. 2020 Sep 15;173(6):426-435.

33. Nam KH, Kie JH, Lee MJ, Chang TI, Kang EW, Kim DW, Lim BJ, Park JT, Kwon YE, Kim YL, Park KS, An SY, Oh HJ, Yoo TH, Kang SW, Choi KH, Jeong HJ, Han DS, Han SH. Optimal proteinuria target for renoprotection in patients with IgA nephropathy. PLoS One. 2014;9(7):e101935.

34. Hallan SI, Orth SR. Smoking is a risk factor in the progression to kidney failure. Kidney Int. 2011 Sep;80(5):516-23.

35. de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol. 2009 Sep;20(9):2075-84.

36. Diabetes Control and Complications Trial Research Group. Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86.

37. Sachdeva B, Zulfiqar H, Aeddula NR. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 8, 2023. Peritoneal Dialysis.